Bone Biologics Corporation
Bone Biologics Corporation (BBLG) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
bblg · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Bone Biologics Corporation (BBLG) measures how much investors pay for each dollar of the company's trailing earnings. BBLG's current PE ratio of N/A is calculated by dividing its stock price of $1.25 by its TTM earnings per share of -$1.59.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2008 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Devices · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Bone Biologics CorporationYou BBLG | $2M | N/A | — | -$1.59 |
 Biodexa Pharmaceuticals Plc BDRX | $1M | N/A | — | -$113.82 |
 DIH Holding US, Inc. DHAI | $0M | N/A | — | -$6.07 |
 GlucoTrack, Inc. GCTK | $0M | N/A | — | -$21.56 |
 HeartSciences Inc. HSCS | $4M | N/A | — | -$9.34 |
 InMed Pharmaceuticals Inc. INM | $3M | N/A | — | -$8.36 |
 Corvex, Inc. MOVE | $13M | N/A | — | -$0.02 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-2.65 | — | |
2024-12-31 FY2024 | — | $-2.71 | — | |
2023-12-31 FY2023 | — | $-34.01 | — | |
2022-12-31 FY2022 | — | $-31.19 | — | |
2021-12-31 FY2021 | — | $-37.46 | — | |
2020-12-31 FY2020 | — | $-35.78 | — | |
2019-12-31 FY2019 | — | $-67.15 | — | |
2018-12-31 FY2018 | — | $-3173.35 | — | |
2017-12-31 FY2017 | — | $-6523.59 | — | |
2016-12-31 FY2016 | — | $-24764.59 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Bone Biologics Corporation (BBLG) measures how much investors pay for each dollar of the company's trailing earnings. BBLG's current PE ratio of N/A is calculated by dividing its stock price of $1.25 by its TTM earnings per share of -$1.59.
Frequently asked questions
BBLG pe ratio · 6 questionsBBLG's current PE ratio is N/A as of 2026-06-08, based on a stock price of $1.25 and TTM EPS of -$1.59. Data sourced from Financial Modeling Prep via BBLG's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Bone Biologics Corporation SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08